NEUROBID

Neuroscience on Barriers in Development

Coordinatore	MEDIZINISCHE HOCHSCHULE HANNOVER    more  Organization address address: Carl-Neuberg-Strasse 1 city: HANNOVER postcode: 30625 contact info Titolo: Prof. Nome: Olaf Cognome: Dammann Email: send email Telefono: +49 511 5326825 Fax: +49 511 5326827
Nazionalità Coordinatore	Germany [DE]
Sito del progetto	http://www.neurobid.eu
Totale costo	4˙194˙375 €
EC contributo	2˙996˙324 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2009-single-stage
Funding Scheme	CP-FP
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-01-01   -   2013-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	MEDIZINISCHE HOCHSCHULE HANNOVER  Organization address address: Carl-Neuberg-Strasse 1 city: HANNOVER postcode: 30625 contact info Titolo: Prof. Nome: Olaf Cognome: Dammann Email: send email Telefono: +49 511 5326825 Fax: +49 511 5326827	DE (HANNOVER)	coordinator	455˙876.60
2	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Dr. Nome: Jean-François Cognome: Ghersi-Egea Email: send email Telefono: +33 4 78 77 87 59 Fax: +33 4 78 77 86 16	FR (PARIS)	participant	602˙970.00
3	UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT  Organization address address: JOSEF-SCHNEIDER-STRASSE 2 city: WUERZBURG postcode: 97080 contact info Nome: Werner Cognome: Buser Email: send email Telefono: +49 931 20159420 Fax: +49 931 20155053	DE (WUERZBURG)	participant	343˙564.00
4	UNIVERSITAIR MEDISCH CENTRUM UTRECHT  Organization address address: HEIDELBERGLAAN 100 city: UTRECHT postcode: 3584 CX contact info Titolo: Ms. Nome: Margot Cognome: Van Der Starre Email: send email Telefono: +31 88 7556422 Fax: +31 88 7555018	NL (UTRECHT)	participant	340˙913.60
5	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD  Organization address address: University Offices, Wellington Square city: OXFORD postcode: OX1 2JD contact info Titolo: Ms. Nome: Chantelle Cognome: Alderson Email: send email Telefono: 441865000000 Fax: 441865000000	UK (OXFORD)	participant	333˙112.80
6	GOETEBORGS UNIVERSITET  Organization address address: VASAPARKEN city: GOETEBORG postcode: 405 30 contact info Titolo: Dr. Nome: Emilia Cognome: Rung Email: send email Telefono: +46 31 7865238 Fax: +46 31 7864355	SE (GOETEBORG)	participant	329˙149.00
7	SIMCYP LIMITED  Organization address address: LEAVYGREAVE ROAD 40 city: SHEFFIELD postcode: S3 7RD contact info Titolo: Ms. Nome: Zoe Cognome: Kelly Email: send email Telefono: +44 114 2922323 Fax: +44 114 2922333	UK (SHEFFIELD)	participant	240˙592.00
8	Angewandte Biotechnologie GmbH  Organization address address: Moosstrasse 99a city: Salzburg postcode: 5020 contact info Titolo: Dr. Nome: Hans-Christian Cognome: Bauer Email: send email Telefono: +43 662 8044 5601 Fax: +43 662 8044 168	AT (Salzburg)	participant	197˙266.00
9	Nathalie Strazielle  Organization address address: Rue du Dr Bonhomme 34 city: Lyon postcode: 69008 contact info Titolo: Dr. Nome: Nathalie Cognome: Strazielle Email: send email Telefono: +33 4 78 09 11 79	FR (Lyon)	participant	152˙880.00
10	UNIVERSITY OF MELBOURNE  Organization address address: PARKVILLEOFFICE OF THE VICE CHANCELLOR city: MELBOURNE postcode: 3010 contact info Titolo: Mr. Nome: Adriaan Cognome: Adolph Email: send email Telefono: +61 3 8344 2016 Fax: +613 9347 6739	AU (MELBOURNE)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Brain diseases are one of the most prevalent groups of diseases in Europe with estimated annual costs amounting to €386 billion (1). Data collected by the WHO suggest that brain diseases are responsible for 35% of Europe’s total disease burden (1). In the treatment of neurological disease, the blood brain barrier (BBB) still represents an obstacle for the delivery of drugs to the brain and thus a major challenge for the development of therapeutic regimens. Understanding the molecular basis and functioning of the BBB in health and disease, including transport mechanisms across the BBB, therefore holds significant potential for future strategies to prevent and ameliorate neurological disease. Recent research indicates that some neurological disorders have a developmental etiologic component. The major goal of the NEUROBID project is thus to understand the molecular mechanisms and function of the BBB in health and disease both in the developing brain and the adult central nervous system. With an interdisciplinary consortium from the fields of developmental neurobiology and BBB research, NEUROBID aims to (i) understand the involvement of normal and disturbed BBB function in normal and abnormal brain development and (ii) to develop novel strategies for drug delivery to the brain. Unique transport mechanisms across the BBB will be used to target potential therapeutic macromolecular and cellular agents specifically to the brain barriers and transport them into the brain. The main target disorders of NEUROBID are non-inherited neurodevelopmental disorders arising from perinatal adverse exposure, such as cerebral palsy, and classic adult neurological disorders such as multiple sclerosis and stroke. In the long term, NEUROBID hopes to pave the way for new treatment strategies and thus reduce the economic and social burden of neurological disease. 1. Olesen J, et al. Consensus document on European brain research. J Neurol Neurosurg Psychiatry 2006;77 Suppl 1:i1-49.'